ASCO 2017 - Relapsed/refractory multiple myeloma: LCAR-B38M yields 100% ORR in phase 1 trial

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • At a maximum tolerated dose of 5mm/kg cells, interim results in this phase 1 trial of the immunotherapeutic agent LCAR-B38M (Legend Biotech) CAR-T targeting B cell maturation antigen in multiple myeloma include 100% ORR, with 18 pts reaching CR or near CR status.

Why this matters...